ADA Scientific Sessions 2025 Abstract

The Oral Apelin Receptor Agonist Azelaprag Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide

By Yan Wang, Shijun Yan, Matthew Banicki, Paul D. Rubin

Experiments in animalsInterventions

The paper

Yan Wang, Shijun Yan, Matthew Banicki, Paul D. Rubin

Richmond

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, oral 225-OR

doi.org/10.2337/db25-225-or

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes